Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sheraz Mian headshot

Top Analyst Reports for Pfizer, Progressive & PNC

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Pfizer Inc. (PFE), The Progressive Corporation (PGR), and The PNC Financial Services Group, Inc. (PNC).

Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

by Zacks Equity Research

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q2

by Zacks Equity Research

Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.

Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

by Zacks Equity Research

On BioNTech's (BNTX) second-quarter earnings call, investors are expected to focus on the sales performance of its COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer.

Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know

by Zacks Equity Research

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

The Zacks Analyst Blog Highlights GSK, Merck, Pfizer, Sanofi and AstraZeneca

by Zacks Equity Research

GSK, Merck, Pfizer, Sanofi and AstraZeneca are part of Zacks top Analyst Blog.

Kinjel Shah headshot

Pharma Stock Roundup: MRK, PFE, SNY Q2 Earnings & Sales Beat, GSK Results Mixed

by Kinjel Shah

GSK plc (GSK), Merck (MRK), Pfizer (PFE), Sanofi (SNY) and AstraZeneca (AZN) announce second-quarter results

GDP Growth Rate Contracts for Two Straight Quarters

by Zacks Equity Research

GDP Growth Rate Contracts for Two Straight Quarters.

Pfizer (PFE) Q2 Earnings Top, COVID Products Drive Sales

by Zacks Equity Research

Pfizer (PFE) beats estimates for Q2 earnings and sales. It maintains the sales forecast for COVID products, Comirnaty and Paxlovid.

Mark Vickery headshot

Q2 GDP -0.9%, So We're in a Recession... Right?

by Mark Vickery

It's a back-of-the-envelope calculation, this notion that two negative-growth quarters in a row constitutes a recession, but analysts are hesitating in real time to paste the "big R" onto our current economic condition.

Pfizer (PFE) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 16.57% and 5.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Is iShares MSCI USA Value Factor ETF (VLUE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VLUE

Drug, Biotech Stocks' Q2 Earnings on Jul 28: MRK, PFE & More

by Zacks Equity Research

Let's analyze how the five pharma/drug/biotech companies are placed before the quarterly earnings release on Jul 28.

GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance

by Zacks Equity Research

GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.

Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo

by Zacks Equity Research

Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.

Is First Trust Rising Dividend Achievers ETF (RDVY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RDVY

Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.

Markets Wait For Fed FOMC, Big Tech Earnings and Economic Data

by Zacks Equity Research

Markets Wait For Fed FOMC, Big Tech Earnings and Economic Data.

Mark Vickery headshot

Big Week for Q2 Earnings, Economic Data

by Mark Vickery

This will be the biggest week for stock market data -- economic prints and Q2 earnings -- so far.

Derek Lewis headshot

Pfizer Q2 Preview: Quarterly Estimates Display Robust Growth

by Derek Lewis

The Zacks - Medical Sector has held up relatively well year-to-date, decreasing approximately 12% in value vs. the S&P 500's decline of 15%.

Earnings Data Deluge

by Zacks Equity Research

Earnings Data Deluge

Mark Vickery headshot

Markets Look to Finish Another Up-Week; AMX, TWTR in Different Q2 Directions

by Mark Vickery

Its the Dow that currently trades in the green this morning, partially on strong Q2 results from American Express (AXP).

AbbVie (ABBV) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Olema (OLMA) Up on FDA Fast Track Tag for Breast Cancer Drug

by Zacks Equity Research

The FDA bestows a Fast Track designation to Olema's (OLMA) novel pipeline candidate, OP-1250, for the treatment of ER+/HER2- metastatic breast cancer. Stock up.

Sweta Killa headshot

Healthcare ETFs in Focus Ahead of Q2 Earnings

by Sweta Killa

The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfolio.